Anagrelide hydrochloride for essential thrombocythemia

Bibliography

• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of the haematopoietic and lymphoid tissue. IARC Press; Lyon, France: 2008
   Google Scholar
• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29:3179-84
   PubMed Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012;26:716-19
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70
   PubMed Web of Science ®Google Scholar
• Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica 2009;94:865-9
   PubMed Web of Science ®Google Scholar
• Osca-Gelis G, Puig-Vives M, Saez M, et al. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 2013;98:e95-7
   PubMed Web of Science ®Google Scholar
• Cervantes F. Management of essential thrombocythemia. Hematol Am Soc Hematol Educ Program 2011;2011:215-21
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larrán A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-90
   PubMed Web of Science ®Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 2012;30:2995-3001
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62
   PubMed Web of Science ®Google Scholar
• Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-4
   PubMed Web of Science ®Google Scholar
• Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997;23:425-31
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Arellano-Rodrigo E, et al. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol 2013;161:865-71
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-10
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70
   PubMed Web of Science ®Google Scholar
• Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352-75
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32
   PubMed Web of Science ®Google Scholar
• Birgegård G. Pharmacological management of essential thrombocythemia. Expert Opin Pharmacother 2013;14:1295-306
   PubMed Web of Science ®Google Scholar
• Wasserman LR, Berk PD, Berlin NI. editors. Polycythemia vera and the myeloproliferative disorders. W.B. Saunders; Philadelphia: 1995
   Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6
   PubMed Web of Science ®Google Scholar
• Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007;21:277-80
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 2011;152:81-8
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-13
   PubMed Web of Science ®Google Scholar
• Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29:2410-15
   PubMed Web of Science ®Google Scholar
• Passamonti F, Lazzarino M. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma 2003;44:1483-8
   PubMed Web of Science ®Google Scholar
• Reilly JT. Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists. Hematology (Am Soc Hematol Educ Program) 2012;17:187-92
   Google Scholar
• Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013;6:49-58
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Exp Rev Hematol 2011;4:637-55
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013;122:893-901
   PubMed Web of Science ®Google Scholar
• Fleming JS, Buyniski JP. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 1979;15:373-88
   PubMed Web of Science ®Google Scholar
• Gilbert HS. Clinical status of anagrelide: a selective agent for the control of thrombocythemia in myeloproliferative disorders [abstract]. Cancer Invest 1991;9:343-4
   Google Scholar
• Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5:1781-6
   PubMed Web of Science ®Google Scholar
• Besses C, Kiladjian JJ, Griesshammer M, et al. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res 2013;37:162-8
   PubMed Web of Science ®Google Scholar
• Solberg LA Jr, Tefferi A, Oles KJ, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-80
   PubMed Web of Science ®Google Scholar
• Mazur EM, Rosmarin AG, Sohl PA, et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-7
   PubMed Web of Science ®Google Scholar
• Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-9
   PubMed Web of Science ®Google Scholar
• Ahluwalia M, Donovan H, Singh N, et al. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J Thromb Haemost 2010;8:2252-61
   PubMed Web of Science ®Google Scholar
• Hong Y, Wang G, Del Arroyo AG, et al. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006;20:1117-22
   PubMed Web of Science ®Google Scholar
• Spencer CM, Brogden RN. Anagrelide. A review of its pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994;47:809-22
   PubMed Web of Science ®Google Scholar
• Bellucci S, Legrand C, Boval B, et al. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol 1999;104:886-92
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Ollig S, Schmitt-Gräff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 2005;20:1071-6
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost 2006;32(4 Pt 2):352-61
   PubMedGoogle Scholar
• Thiele J, Kvasnicka HM, Fuchs N, et al. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003;88:1130-8
   PubMed Web of Science ®Google Scholar
• Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999;106:682-8
   PubMed Web of Science ®Google Scholar
• Emadi A, Spivak JL. Anagrelide: 20 years later. Expert Rev Anticancer Ther 2009;9:37-50
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xagrid: EPAR- Product information. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000480/WC500056557.pdf [Accessed 26 August 2013]
   Google Scholar
• Martínez-Sellés M, Datino T, Figueiras-Graillet L, et al. Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. Clin Drug Invest 2013;33:45-54
   PubMed Web of Science ®Google Scholar
• Wang G, Franklin R, Hong Y, Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 2005;146:324-32
   PubMed Web of Science ®Google Scholar
• Petrides PE, Gisslinger H, Steurer M, et al. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. Clin Ther 2009;31:386-98
   PubMedGoogle Scholar
• Besses C, Zeller W, Álvarez-Larrán A, et al. Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18-50 years) and elderly (≥ 65 years) patients with essential thrombocythemia. Int J Clin Pharmacol Ther 2012;50:787-96
   PubMed Web of Science ®Google Scholar
• Proietti R, Rognoni A, Ardizzone F, et al. Atypical Takotsubo syndrome during anagrelide therapy. J Cardiovasc Med (Hagerstown) 2009;10:546-9
   PubMed Web of Science ®Google Scholar
• Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia [Letter]. Hematologica 2004;89:1394-5
   PubMedGoogle Scholar
• Besses C, Martínez-Sellés M. Anagrelide and cardiovascular events. Much ado about nothing? Leuk Res 2011;35:1543-4
   PubMed Web of Science ®Google Scholar
• Berger A, Arnold J, Dukstein E, et al. 111Indium-labeled autologous platelet survival Turing aggregation inhibition by anagrelide in normal male volunteers [abstract C56]. Clin Pharmacol Ther 1983;33:219
   Web of Science ®Google Scholar
• Plapp F, Sinor L, Schmitz R, et al. Effect of anagrelide on platelet counts and size [abstract C52]. Clin Pharmacol Ther 1983;22:223
   Google Scholar
• Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;29:325-8
   Google Scholar
• Taylor R, Fleming S, Arnold J. The effect on platelet of a stable orally-active imidazoquinazoline [abstract]. J Clin Pharmacol 1984;24:423
   Google Scholar
• Silverstein MN, Petitt RM, Solberg LA Jr, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-4
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, De Sanctis V, Chistolini A, et al. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Hematologica 1992;77:315-17
   PubMed Web of Science ®Google Scholar
• Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Hematologica 1992;77:40-3
   PubMed Web of Science ®Google Scholar
• McIntyre KJ, Hoagland HC, Silverstein MN, Petitt RM. Essential thrombocythemia in young adults. May Clin Proc 1981;66:149-54
   Google Scholar
• Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust NZ J Med 1999;29:29-35
   PubMedGoogle Scholar
• Lackner H, Urban C, Beham-Schmid C, et al. Treatment of children with anagrelide for thrombocythemia. J Pediatr Hematol Oncol 1998;20:469-73
   PubMed Web of Science ®Google Scholar
• Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 1998;24:9-13
   PubMed Web of Science ®Google Scholar
• Chintagumpala MM, Steuber CP, Mahoney DH Jr, et al. Essential thrombocythemia in a child: management with anagrelide. Am J Pediatr Hematol Oncol 1991;13:52-6
   PubMedGoogle Scholar
• Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 1998;55:1979-86
   PubMed Web of Science ®Google Scholar
• Petrides PE. Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost 2006;32:399-408
   PubMed Web of Science ®Google Scholar
• Griesshammer M. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide. Expert Rev Hematol 2009;2:227-36
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 2006;66:111-31
   PubMed Web of Science ®Google Scholar
• Harrison CN. Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncol 2005;1:609-18
   PubMedGoogle Scholar
• Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999;36(1 Suppl 2):23-5
   PubMedGoogle Scholar
• Anagrelide Study Group. Anagrelide therapy for thrombocythemia states: experience in 577 patients. Am J Med 1992;92:69-76
   PubMed Web of Science ®Google Scholar
• Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-6
   PubMed Web of Science ®Google Scholar
• Laguna MS, Kornblihtt LI, Marta RF, et al. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-61
   PubMed Web of Science ®Google Scholar
• Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6
   PubMed Web of Science ®Google Scholar
• Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-46
   PubMed Web of Science ®Google Scholar
• Penninga E, Jensen BA, Hansen PB, et al. Anagrelide treatment in 52 patients with chronic myeloproliferative disease. Clin Lab Haematol 2004;26:335-40
   PubMedGoogle Scholar
• Mazzucconni MG, Redi R, Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004;89:1306-13
   PubMedGoogle Scholar
• Frutchman SM, Petitt RM, Gilbert HS, et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29:481-91
   PubMedGoogle Scholar
• Giralt M, Navas V, Hernández-Nieto L, et al. Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocythemia: Spanish registry of essential thrombocythemia [Article in Spanish]. Med Clin (Barc) 2009;133:89-90
   Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113:4829-33
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda LC, Pereira A, Cervantes F, et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol 2013;92:771-5
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012;119:1363-9
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 2013;121:4778-81
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
   PubMed Web of Science ®Google Scholar
• Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009;27:2991-9
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-8
   PubMed Web of Science ®Google Scholar
• Imbert M, Pierre R, Thiele J, et al. Essential thrombocythemia. In: Jaffe ES, Harris NL, Stein H, et al. editors. Pathology and genetics: tumours of haematopoietic and lymphoid tissue. World health organization. Classification of tumours. IARC Press; Lyon, France; 2001. p. 39-41
   Google Scholar
• Buxhofer-Ausch V, Gisslinger H, Thiele J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 2012;87:669-72
   PubMed Web of Science ®Google Scholar
• Engel PJ, Johnson H, Baughman RP, Richards AI. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med 2005;143:311-13
   PubMedGoogle Scholar
• Birgegård G, Björkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004;89:520-7
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res 2011;35:1557-63
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Besses C, Griesshammer M, et al. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged > 80 years: an interim analysis of the EXELS study. Clin Drug Invest 2013;33:55-63
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Besses C, Griesshammer M, et al. Combination of cytoreductive therapies in patients with essential thrombocythemia: a preliminary report from the E.X.E.L.S. Study. Blood (ASH Annual Meeting Abstracts) 2012;120:2842
   Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-33
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012;120:1197-201
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-75
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122(13):2176-84
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-13
   PubMed Web of Science ®Google Scholar
• Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN alpha. Blood 2013;122:1464-77
   PubMed Web of Science ®Google Scholar
• Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012;129:1409-11
   Google Scholar